The two drugs that extended life in this mouse study are already prescribed to people.
About SN111 Claims
Claims - Subnet 111@DeSciClaimsThe two drugs that extended life in this mouse study are already prescribed to people. Neither was designed for #ageing. One is rapamycin, an immunosuppressant given after organ transplants. The other is trametinib, a melanoma drug sold as Mekinist. Linda Partridge's group at the Max Planck Institute for Biology of Ageing in Cologne ran 876 mice in 4 groups: untreated controls, trametinib, rapamycin, and both drugs together. All dosing was through the food, from 6 months of age. Trametinib alone raised median lifespan by 7-10%. Rapamycin alone raised median lifespan by ~17%. Together: The effects add up to 27-34%. Combined drug treatment delayed tumour growth, and reduced brain inflammation in old female mice. The study used 1 strain of mouse from 1 lab, with no independent replication. The researchers followed only 1 of the 3 cohorts to the end of life. The mice on rapamycin had raised blood glucose. On most of the fitness tests, the treated mice performed no differently from the controls. Gkioni et al., 2025, Nature Aging. This paper went through Claims this week: 15 claims, each tied to its evidence.
SN111 Claims at a glance
SN111, Claims (α token Ё), is one of the independent markets on the Bittensor network, each with its own α token and its own price. Its α currently trades at 0.004171 τ (≈ $1.20), against 5,492 τ of pool liquidity. On-chain, the best-delegated validator on it yields about 35.45% APR (simple) and 42.54% APY (compounded), emissions add 0.000000 τ to the pool each block, epochs run every 360 blocks. It was registered at block #5,615,562.
More from SN111 Claims
Taosis indexes announcements, articles, posts and releases about Bittensor subnets from their own channels and keeps a record of each. The text above is the source’s; the figures are read from the chain by Taosis.